Back to top

Analyst Blog

SurModics, Inc. (SRDX - Analyst Report), a provider of surface modification and drug delivery technologies to the healthcare industry, recently revealed that it has appointed Andy LaFrence as the chief financial officer (CFO) and Vice President of finance. He will take over the reins effective February 12, 2013. LaFrence will replace Timothy Arens, the current interim CFO at SurModics.

Going forward, Timothy Arens will assume responsibility as the Vice President of corporate development and strategy. He will be responsible for framing strategies and assessing growth opportunities for the Medical Device and In Vitro Diagnostics segments at Surmodics. We note that SurModics currently operates through these two divisions.

The new CFO will be responsible for leading the entire financial activities at SurModics. His will be in charge of activities, such as controlling, financial planning and analysis, treasury, tax, audit and investor relations.

LaFrence, a certified public accountant, brings with him more than 20 years of experience to SurModics pertaining to finance and capital markets. LaFrence has donned many important roles in his illustrious career. Previously, he was the CFO of CNS Therapeutics (now a wholly owned subsidiary of Covidien plc (COV - Analyst Report)). Prior to that, he acted as an audit partner at KPMG, where he concentrated on supporting public and private, high-growth medical technology, pharmaceutical and biotechnology entities.

Taking into account LaFrence’s vast experience in the finance and capital markets, he can easily be labeled as a veteran in that field. LaFrence’s comprehensive sector know-how and expertise is expected to be beneficial to SurModics.

We have a long-term Neutral recommendation on SurModics. Also, it holds a short-term Zacks #3 Rank (Hold). However, Quidel Corporation (QDEL - Snapshot Report), which operates in the same industry as SurModics, appears to be better- positioned. The stock carries a Zacks #2 Rank (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
SUPER MICRO… SMCI 27.00 +10.25%
CANADIAN SO… CSIQ 38.34 +8.18%
CENTURY ALU… CENX 26.97 +7.97%
WILLDAN GRO… WLDN 11.38 +5.86%
AROTECH COR… ARTX 3.78 +5.59%